Please assess the completion status of the following clinical trial:

Trial Title: Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years old hospitalized patients with bacteremia from any source with isolation of an enterobacteria in blood cultures.~2. Active empiric treatment with antipseudomonal betalactamic at 48 hours from the symptoms of sepsis and the blood culture.The patient could have received any other type of antibiotic therapy up to 24 hours after blood extraction.~3. Microorganism susceptible at least one treatment from the experimental arm.~4. Patients with intravenous treatment at least 3 days from the randomization o 5 days from the initial blood culture.~5. Patients to sign the informed consent form.~Exclusion Criteria:~1. Palliative care or life expectance \< 90 days.~2. Pregnancy or lactation period.~3. To isolate the Extended-spectrum β-lactamases producing Enterobacteriaceae~4. Late randomization \>48 hours after the enterobacteriaceae blood culture´s identification~5. Severe neutropenic (\< 500 céls/mm3) at the randomization.~6. Treatment of infection \> 28 days (endocarditis and osteomyelitis) or meningitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Antipseudomonal beta-lactam antibiotic (Type: EXPERIMENTAL): 1. Ampicillin 2g IV/6h~2. Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~3. Cefuroxime 750-1000 mg IV/8h~4. Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~5. Amoxicillin/clavulanate 1000/125 mg IV/8h~6. Ciprofloxacin 400 mg IV/12h~7. Ertapenem 1-2g/24h.
- De-escalation(short-spectrum antibiotic) (Type: ACTIVE_COMPARATOR): * Piperacillin/tazobactam 4/0.5 g IV/8h~* Meropenem 1-2 g IV/8h~* Imipenem 0.5 g IV/6h - 1g IV/6h~* Aztreonam 1-2 g IV/8h~* Ceftazidime 1-2 g IV/8h~* Cefepime 2 g IV/8-12h

Based on this trial design, predict the completion outcome and termination type (if applicable).